StemCell Therapy

DUBLIN, Oct. 13, 2022 /PRNewswire/ -- The "Monoclonal Antibodies Market Size, Share & Trends Analysis Report by Source Type (Chimeric, Murine, Humanized, Human), by Production Type (In Vivo, In Vitro), by Application, by End-use, by Region, and Segment Forecasts, 2022-2030" report has been added to ResearchAndMarkets.com's offering.

Research and Markets Logo

The global monoclonal antibodies market is projected to reach USD 494.53 billion by 2030, at a compound annual growth rate (CAGR) of 11.30%

Increasing research and development activities aimed at the development of novel therapeutic monoclonal antibodies (mAbs) and supportive government initiatives for biologics production are anticipated to drive market growth in the forecast period.

The rising demand for personalized medicine is likely to positively affect the development of therapeutic mAb targeted therapies that are tailored to individual requirements. Moreover, the therapeutic use of mAbs offers several advantages such as fewer adverse effects, specificity of treatment, and large-scale production capabilities, as compared to conventional treatment options, and can significantly drive market growth.

In addition, several government entities are fueling clinical research activities and expanding the scope of applications for mAb therapies. For instance, in June 2022, the National Institutes of Health launched clinical trials for the evaluation of dupilumab, for the reduction of asthma attacks and the improvement of lung functionality in children.

Similarly, in March 2021, the U.S. Department of Health and Human Services invested USD 150 million in increasing patient access to monoclonal antibody therapeutics for COVID-19. Such initiatives are expected to increase the adoption of monoclonal antibodies and strengthen growth prospects.

Furthermore, technological advancements in genetic engineering, DNA cloning, and various peptide and protein display technologies have led to the generation and optimization of recombinant mAbs. Demand for such recombinant antibodies is driven by increasing commercial prospects and quality requirements that may not be fulfilled by hybridoma technologies. Hence, with the increasing commercial viability of recombinant technologies, the market is expected to witness significant growth.

Story continues

The COVID-19 pandemic has created several market expansion opportunities by fueling the development of several mAbs directed against the SARS-CoV-2 virus.

As mAbs represent a promising alternative for mitigation of the disease due to their safety and effectiveness, several mAbs such as Eli Lilly's bebtelovimab, and GlaxoSmithKline & Vir Biotechnology's sotrovimab have attained emergency use authorizations from the U.S. FDA. Such authorizations are likely to broaden the horizons for the growth of mAbs applications and propel market growth.

Monoclonal Antibodies Market Report Highlights

By source type, the human mAbs segment held the largest share of 54.07% in 2021 due to the low immunogenicity offered and increasing cancer treatment applications of these antibodies

In vitro production type held a dominating share of 78.45% in 2021 due to the low contamination levels offered by the technique and the availability of advanced bio-manufacturing capabilities

The oncology segment dominated the market in 2021 due to the rising number of approvals for mAb cancer therapeutics and increasing scientific and patient awareness about such therapies

Hospitals accounted for the largest share of the end-use segment in 2021 due to the widespread use of mAbs for cancer treatment in hospitals and increasing healthcare expenditure favoring the adoption of such therapeutics

North America accounted for 46.2% of the market value in 2021 due to the availability of advanced healthcare infrastructure, high growth in cancer incidence, and local presence of key players such as Pfizer Inc., Amgen, Inc., and Merck & Co., among others

The Asia Pacific is projected to witness the highest growth rate in the forecast period due to the availability of a large patient pool for cancer treatment and expanding the scope of clinical research prospects for mAbs.

Key Topics Covered:

Chapter 1 Methodology and Scope

Chapter 2 Executive Summary2.1 Market Outlook2.2 Market Summary

Chapter 3 Monoclonal Antibodies Market Variables, Trends & Scope3.1 Market Trends & Outlook3.2 Market Segmentation & Scope3.3 Market Driver Analysis3.3.1 Increasing Incidences Of Chronic Diseases3.3.2 Technological Advancements3.3.3 Growing Awareness Levels3.4 Market Restraint Analysis3.4.1 High Cost Of Therapeutic Mabs3.5 SWOT Analysis, by Factor (Political & Legal, Economic, and Technological)3.6 Porter's Five Forces Analysis3.7 COVID-19 Impact Analysis3.8 Penetration & Growth Prospect Mapping

Chapter 4 Monoclonal Antibodies Market - Segment Analysis, by Source Type, 2018 - 2030 (USD Billion)4.1 Monoclonal Antibodies Market: Source Type Movement Analysis4.2 Murine4.2.1 Murine Market Estimates And Forecast, 2018 - 2030 (USD Billion)4.3 Chimeric4.4 Humanized4.5 Human

Chapter 5 Monoclonal Antibodies Market - Segment Analysis, By Production Type, 2018 - 2030 (USD Billion)5.1 Monoclonal Antibodies Market: Production Type Movement Analysis5.2 In Vivo5.2.1 In Vivo Market Estimates And Forecast, 2018 - 2030 (USD Billion)5.3 In Vitro

Chapter 6 Monoclonal Antibodies Market - Segment Analysis, By Application, 2018 - 2030 (USD Billion)6.1 Monoclonal Antibodies Market: Application Movement Analysis6.2 Oncology6.2.1 Oncology Market Estimates And Forecast, 2018 - 2030 (USD Billion)6.3 Autoimmune Diseases6.4 Infectious Diseases6.5 Neurological Diseases

Chapter 7 Monoclonal Antibodies Market - Segment Analysis, By End-Use, 2018 - 2030 (USD Billion)7.1 Monoclonal Antibodies Market: End-Use Movement Analysis7.2 Hospitals7.2.1 Hospitals Market Estimates And Forecast, 2018 - 2030 (USD Billion)7.3 Specialty Centers

Chapter 8 Monoclonal Antibodies Market - Segment Analysis, By Region, 2018 - 2030 (USD Billion)8.1 Monoclonal Antibodies Market: Regional Movement Analysis

Chapter 9 Competitive Analysis

Abbott Laboratories

Amgen Inc.

Astrazeneca plc

Bayer AG

Biogen Inc.

Bristol Myers Squibb

Daiichi Sankyo Company, Limited

Eli Lilly and Company

F. Hoffman-La Roche Ltd.

GlaxoSmithKline plc

Johnson & Johnson Services, Inc.

Merck & Co. Inc.

Merck Kgaa

Novartis AG

Novo Nordisk A/S

Pfizer Inc

Sanofi S.A.

Thermo Fisher Scientific, Inc.

Viatris Inc.

For more information about this report visit https://www.researchandmarkets.com/r/1y2bed

Media Contact:

Research and MarketsLaura Wood, Senior Managerpress@researchandmarkets.comFor E.S.T Office Hours Call +1-917-300-0470For U.S./CAN Toll Free Call +1-800-526-8630For GMT Office Hours Call +353-1-416-8900U.S. Fax: 646-607-1907Fax (outside U.S.): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

Cision

View original content:https://www.prnewswire.com/news-releases/global-monoclonal-antibodies-mabs-markets-2018-2021--2022-2030---increasing-rd-activities-aimed-at-the-development-of-novel-therapeutic-mabs-301648431.html

SOURCE Research and Markets

View post:
Global Monoclonal Antibodies (mAbs) Markets, 2018-2021 & 2022-2030 - Increasing R&D Activities Aimed at the Development of Novel Therapeutic mAbs -...

This entry was posted on October 15, 2022 at 1:46 am and is filed under Personalized Medicine. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |